Dynorphin A Impairs Mitochondrial Biogenesis in Osteosarcoma Cells by Increasing SP‐1

Mitochondria are vital for energy generation, apoptosis control, and cellular metabolism. As a result, they represent an attractive therapeutic target in cancer treatment, particularly osteosarcoma (OS). Despite evidence indicating that Dynorphin A exhibits anti-tumor characteristics via multiple mechanisms, its influence on the physiology of osteosarcoma (OS) has not been thoroughly investigated. In this study, we explore the impacts of Dynorphin A on mitochondrial function and biogenesis within human OS U2OS cells. Human osteosarcoma (U2OS) cells were treated with Dynorphin A at varying concentrations for 48 h. Cell viability and cytotoxicity were assessed using the Cell Counting Kit-8 (CCK-8) and LDH assay, respectively. Mitochondrial function was evaluated by measuring complex IV activity, oxygen consumption rate (OCR), and ATP production, while mitochondrial biogenesis was analyzed by determining the mtDNA/nDNA ratio, mitochondrial protein expression (NDUFB8 and MTCO<sub>2</sub>), and mitochondrial mass (MitoTracker Red staining). The expression of key mitochondrial regulators (PGC-1α, Nrf1, TFAM) and SP-1 was quantified using real-time RT-PCR and Western blot analysis. Our findings reveal that Dynorphin A notably decreases cell viability and enhances the release of lactate dehydrogenase (LDH)., indicating cytotoxicity. It also impaired mitochondrial function, as evidenced by a decrease in complex IV activity, oxygen consumption, and ATP production. Additionally, Dynorphin A suppressed mitochondrial biogenesis, shown by a reduced mtDNA/nDNA ratio, lower expression of mitochondrial proteins (NDUFB8 and MTCO2), and decreased mitochondrial mass. Furthermore, Dynorphin A downregulated key mitochondrial regulators, including PGC-1α, Nrf1, and TFAM. Notably, Dynorphin A also upregulated SP-1 expression, and silencing SP-1 reversed its effects on mitochondrial function and biogenesis. These findings suggest that Dynorphin A exerts antitumor effects by disrupting mitochondrial function and biogenesis in OS cells.

Authors

Institutions

Publication Details

Journal
Journal of Biochemical and Molecular Toxicology
Published
2025-08-20
DOI
https://doi.org/10.1002/jbt.70451
Citations
1
Primary Topic
Histone Deacetylase Inhibitors Research
Type
article
Field-Weighted Citation Impact
0.81
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Dynorphin A Impairs Mitochondrial Biogenesis in Osteosarcoma Cells by Increasing SP‐1

Jian Zhang, Yuying Dai, Lingyan Hu, Yi Peng
1 citations
Journal of Biochemical and Molecular Toxicology
Histone Deacetylase Inhibitors Research
0.81
article

Dynorphin A Impairs Mitochondrial Biogenesis in Osteosarcoma Cells by Increasing SP‐1

Jian Zhang, Yuying Dai, Lingyan Hu, Yi Peng
article en
1 citations

Abstract

Mitochondria are vital for energy generation, apoptosis control, and cellular metabolism. As a result, they represent an attractive therapeutic target in cancer treatment, particularly osteosarcoma (OS). Despite evidence indicating that Dynorphin A exhibits anti-tumor characteristics via multiple mechanisms, its influence on the physiology of osteosarcoma (OS) has not been thoroughly investigated. In this study, we explore the impacts of Dynorphin A on mitochondrial function and biogenesis within human OS U2OS cells. Human osteosarcoma (U2OS) cells were treated with Dynorphin A at varying concentrations for 48 h. Cell viability and cytotoxicity were assessed using the Cell Counting Kit-8 (CCK-8) and LDH assay, respectively. Mitochondrial function was evaluated by measuring complex IV activity, oxygen consumption rate (OCR), and ATP production, while mitochondrial biogenesis was analyzed by determining the mtDNA/nDNA ratio, mitochondrial protein expression (NDUFB8 and MTCO<sub>2</sub>), and mitochondrial mass (MitoTracker Red staining). The expression of key mitochondrial regulators (PGC-1α, Nrf1, TFAM) and SP-1 was quantified using real-time RT-PCR and Western blot analysis. Our findings reveal that Dynorphin A notably decreases cell viability and enhances the release of lactate dehydrogenase (LDH)., indicating cytotoxicity. It also impaired mitochondrial function, as evidenced by a decrease in complex IV activity, oxygen consumption, and ATP production. Additionally, Dynorphin A suppressed mitochondrial biogenesis, shown by a reduced mtDNA/nDNA ratio, lower expression of mitochondrial proteins (NDUFB8 and MTCO2), and decreased mitochondrial mass. Furthermore, Dynorphin A downregulated key mitochondrial regulators, including PGC-1α, Nrf1, and TFAM. Notably, Dynorphin A also upregulated SP-1 expression, and silencing SP-1 reversed its effects on mitochondrial function and biogenesis. These findings suggest that Dynorphin A exerts antitumor effects by disrupting mitochondrial function and biogenesis in OS cells.

Journal of Biochemical and Molecular ToxicologyVol. 39(9)
Qianjiang Central Hospital (CN), Wuhan No. 7 Hospital (CN), Wuhan No.9 Hospital (CN), Huanggang Central Hospital (CN)
Affordable and clean energy
Openalex Percentile: Top 24%
Histone Deacetylase Inhibitors Research
0.81
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.